Anatara Lifesciences (ASX:ANR) obtained a standard patent for its gastrointestinal re-programming product, known as GaRP, in Hong Kong, according to a Monday filing with the Australian bourse.

The patent is valid for 20 years from Oct. 9, 2020, and follows a similar grant from the European Union in September 2024, and in Australia on Jan. 28 of this year.

Anatara Lifesciences recently concluded its trial for GaRP as treatment for debilitating symptoms of digestive disorders, including irritable bowel syndrome (IBS), per the filing.

Anatara Lifesciences' shares fell 8% in recent trade.